EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision
   Marinomed Biotech AG begins reviewing strategic options for the Marinosolv
   platform

   06-Oct-2025 / 14:56 CET/CEST
   Disclosure of an inside information acc. to Article 17 MAR of the
   Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
   Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Ad hoc announcement

   Marinomed Biotech AG begins reviewing strategic options for the Marinosolv
   platform

    

   Korneuburg, October 6, 2025 - Ad hoc announcement

   Following the successful recent capital measures, the Management Board of
   Marinomed Biotech AG, with the approval of the Supervisory Board, today
   decided to begin reviewing strategic options for the Marinosolv platform.
   Depending on the progress of the review, the evaluation process could
   include strategic partnerships for the two projects Budesolv and
   Tacrosolv, as well as the involvement of a strategist. Marinomed is
   working with an experienced consulting firm to support this process.

    

   +++ End of ad-hoc announcement +++

    

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: https://www.marinomed.com.

    

   For further inquiries contact:

   Marinomed Biotech AG         
   PR: Luca Horinek
   IR.: Tobias Meister
   T: +43 2262 90300 158
   E-Mail: [1]pr@marinomed.com
   E-Mail: [2]ir@marinomed.com

    

   Disclaimer 

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed and Marinosolv® are registered trademarks of
   Marinomed Biotech AG. These trademarks may be owned or licensed in select
   locations only. 

   End of Inside Information

   ══════════════════════════════════════════════════════════════════════════

   Information and Explanation of the Issuer to this announcement:

    Ad hoc announcement

   Marinomed Biotech AG begins reviewing strategic options for the Marinosolv
   platform

    

   Korneuburg, October 6, 2025 - Ad hoc announcement

   Following the successful recent capital measures, the Management Board of
   Marinomed Biotech AG, with the approval of the Supervisory Board, today
   decided to begin reviewing strategic options for the Marinosolv platform.
   Depending on the progress of the review, the evaluation process could
   include strategic partnerships for the two projects Budesolv and
   Tacrosolv, as well as the involvement of a strategist. Marinomed is
   working with an experienced consulting firm to support this process.

    

   +++ End of ad-hoc announcement +++

    

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: https://www.marinomed.com.

    

   For further inquiries contact:

   Marinomed Biotech AG         
   PR: Luca Horinek
   IR.: Tobias Meister
   T: +43 2262 90300 158
   E-Mail: [3]pr@marinomed.com
   E-Mail: [4]ir@marinomed.com

    

   Disclaimer 

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed and Marinosolv® are registered trademarks of
   Marinomed Biotech AG. These trademarks may be owned or licensed in select
   locations only. 

   ══════════════════════════════════════════════════════════════════════════

   06-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 2208704


    
   End of Announcement EQS News Service


   2208704  06-Oct-2025 CET/CEST

   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2208704&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf

References

   Visible links
   1. mailto:pr@marinomed.com
   2. mailto:ir@marinomed.com
   3. mailto:pr@marinomed.com
   4. mailto:ir@marinomed.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print